Lyra Therapeutics Stock Analysis

Lyra Stock Analysis Notes

About 20.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.61. Lyra Therapeutics recorded a loss per share of 22.9. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 28th of May 2025. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people. To find out more about Lyra Therapeutics contact Maria Palasis at 617 393 4600 or learn more at https://lyratherapeutics.com.

Lyra Therapeutics Investment Alerts

Lyra Therapeutics Upcoming and Recent Events

Lyra Largest EPS Surprises

View All Earnings Estimates

Lyra Therapeutics Environmental, Social, and Governance (ESG) Scores

Lyra Stock Institutional Investors

Note, although Lyra Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lyra Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.47 M.

Lyra Profitablity

Management Efficiency

Lyra Therapeutics has return on total asset (ROA) of (0.3308) % which means that it has lost $0.3308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.0448) %, meaning that it created substantial loss on money invested by shareholders. Lyra Therapeutics' management efficiency ratios could be used to measure how well Lyra Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.54. The current year's Return On Capital Employed is expected to grow to -1.96. At present, Lyra Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 97.5 M, whereas Non Current Assets Total are forecasted to decline to about 13.7 M.

Technical Drivers

As of the 3rd of January, Lyra Therapeutics secures the Mean Deviation of 4.03, risk adjusted performance of (0.12), and Standard Deviation of 5.55. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lyra Therapeutics, as well as the relationship between them.

Lyra Therapeutics Price Movement Analysis

Lyra Therapeutics Insider Trading Activities

Lyra Therapeutics Outstanding Bonds

Lyra Therapeutics Predictive Daily Indicators

Lyra Therapeutics Forecast Models

Lyra Therapeutics' time-series forecasting models are one of many Lyra Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyra Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Lyra Therapeutics Bond Ratings

Lyra Therapeutics financial ratings play a critical role in determining how much Lyra Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lyra Therapeutics' borrowing costs.

Lyra Therapeutics Debt to Cash Allocation

Lyra Therapeutics currently holds 34.38 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lyra Therapeutics has a current ratio of 12.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lyra Therapeutics' use of debt, we should always consider it together with its cash and equity.

Lyra Therapeutics Total Assets Over Time

Lyra Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Lyra Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Lyra Therapeutics Debt Ratio

49.0

It appears about 51% of Lyra Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lyra Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lyra Therapeutics, which in turn will lower the firm's financial flexibility.

Lyra Therapeutics Corporate Bonds Issued

Lyra Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lyra Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lyra shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lyra Therapeutics. By using and applying Lyra Stock analysis, traders can create a robust methodology for identifying Lyra entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lyra analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lyra analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Lyra Therapeutics stock analysis indicators help investors evaluate how Lyra Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lyra Therapeutics shares will generate the highest return on investment. By understating and applying Lyra Therapeutics stock analysis, traders can identify Lyra Therapeutics position entry and exit signals to maximize returns.

When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.